BTIG Maintains a Buy Rating on Boston Scientific Corp (BSX)


In a report released yesterday, Sean Lavin from BTIG maintained a Buy rating on Boston Scientific Corp (NYSE: BSX), with a price target of $45. The company’s shares closed yesterday at $36.43.

According to TipRanks.com, Lavin is a 5-star analyst with an average return of 12.3% and a 60.4% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.

Boston Scientific Corp has an analyst consensus of Strong Buy, with a price target consensus of $40.76, representing an 11.9% upside. In a report issued on October 2, Morgan Stanley also maintained a Buy rating on the stock with a $48 price target.

.

See today’s analyst top recommended stocks >>

Based on Boston Scientific Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.49 billion and net profit of $555 million. In comparison, last year the company earned revenue of $2.22 billion and had a net profit of $283 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts